Skip to main content

Richard Andrew Krasuski

Professor of Medicine
Medicine, Cardiology

Overview


Dr. Richard Krasuski is Director of the Adult Congenital Heart Center at Duke University Medical Center, the Director of Hemodynamic Research, and the Medical Director of the CTEPH Program. He is considered a thought leader in the fields of pulmonary hypertension and congenital heart disease. His research focus is in epidemiologic and clinical studies involving patients with pulmonary hypertension and patients with congenital heart disease. He is involved in multiple multicenter studies through the Alliance for Adult Research in Congenital Cardiology (AARCC). He has also helped to develop multiple research databases in these patient populations. He is Co-PI in the upcoming EPIPHANY Study examining the impact of medical and transcatheter interventions on RV-PA coupling in patients with chronic thromboembolic pulmonary hypertension. Over his career he has mentored over 80 students, residents and fellows and has published over 300 peer reviewed publications, book chapters and meeting abstracts. He is also the Chief Editor of Advances in Pulmonary Hypertension and on the editorial boards of several leading medical journals.

Current Appointments & Affiliations


Professor of Medicine · 2016 - Present Medicine, Cardiology, Medicine

In the News


Published May 11, 2023
1 in 5 Brain Injury Trials Show Errors, Signs of Spin
Published December 8, 2022
Doctors should ask heart patients if they take supplements to manage heart failure
Published May 6, 2019
'No-Spin Zone'? Not in Cardiology

View All News

Recent Publications


Impact of left ventricular assist device implantation on right ventricular-pulmonary arterial coupling assessed by high-fidelity hemodynamics.

Journal Article J Heart Lung Transplant · April 2026 BACKGROUND: Postoperative right ventricular (RV) adaptation to left ventricular assist device (LVAD) implantation remains poorly characterized. RV-pulmonary artery (PA) coupling, defined as the ratio of end-systolic to arterial elastance (Ees/Ea), provides ... Full text Link to item Cite

Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial.

Journal Article Circ Cardiovasc Interv · March 26, 2026 BACKGROUND: The COMPASSION S3 trial was designed to evaluate the safety and effectiveness of the SAPIEN 3 transcatheter heart valve (THV) for transcatheter pulmonic valve replacement in patients with a dysfunctional right ventricular outflow tract (RVOT) c ... Full text Link to item Cite
View All Publications

Recent Grants


Occluflex

Clinical TrialCo-Principal Investigator · Awarded by Occlutech US LLC · 2024 - 2025

Peer Coaching Adaptive Self-Management Interventions for Young Adults with Congenital Heart Disease (CHASM IN ACHD)

ResearchPrincipal Investigator · Awarded by Adult Congenital Heart Association · 2019 - 2023

Insmed TPIP

Clinical TrialPrincipal Investigator · Awarded by Insmed · 2021 - 2023

View All Grants

Education


Harvard Medical School · 1994 M.D.